Case reportPublished 2014
Use of Maraviroc in the prevention and Treatment of Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
We discuss the case of a patient with Progressive Multifocal Leukoencephalopathy (PML), developed after treatment with Natalizumab for 42 months for relapsing remitting multiple sclerosis (RRMS). Imaging was consistent with wide-spread PML with features that portended a high risk of development of Immune Reconstitution Inflammatory Syndrome (IRIS). After completion of plasmapheresis, she was started on oral maraviroc, chemokine receptor 5 antagonists. Our patient did not develop radiological signs or symptoms of clinical IRIS and tolerated maraviroc without adverse side-effects. We propose that maraviroc merits further examination as an agent that may prevent IRIS in patients with natalizumab-associated PML.
Keywords
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Multiple Sclerosis
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Deepti Anbarasan”
- BylineArticles whose byline prints “Jonathan Howard”
- BylineArticles whose byline prints “Lana Zhovtis Ryerson”
